Identification of alterations in the nucleotide sequence of the chromatin remodeling gene PBRM1 in clear cell renal cell carcinoma patients

Kidney cancer is a heterogeneous group of malignant tumors, the vast majority of which are renal cell carcinomas (RCC) of various morphological types, of which the most common is the clear cell renal cell carcinoma (ccRCC). Particular attention in the carcinogenesis of the ccRCC is given to a number of tumor suppressor genes located on the short arm of the third chromosome. One of these genes, which are inactivated in the case of ccRCC is the PBRM1 gene encoding the PBAF SWI/SNF subunit of the chromatin remodeling complex, BAF180. The PBRM1 gene is located on the short arm of the third chromosome in the 3p21 region near the von Hippel-Lindau gene (VHL), the mutation in which is the main event in the occurrence of ccRCC. The aim of our investigation is identification of changes in the nucleotide sequence of the PBRM1 tumor suppressor gene in patients with ccRCC. 210 pairs of DNA samples isolated from ccRCC tissue were studied. Analysis of changes in the nucleotide sequence of DNA was carried out by HRM analysis and direct sequencing. In the PBRM1 gene, two somatic mutations were found (c.233G>A (p.D45N) in exon 2, c.1675-1676delTC in exon 15) which were not described previously, and one known polymorphic variant rs17264436 (in exon 23). The frequency of detected mutations was 0.95 % of cases. Analysis of the allelic association for the polymorphic locus rs17264436 showed a statistically significant increase in the risk of developing advanced kidney cancer in carriers of allele rs17264436*A, which can be used in the development of prognostic marker panels. Perhaps the low frequency of mutations in the samples we studied is due to the fact that the inactivation of the PBRM1 gene takes place in other ways, and may also be due to the ethno-specificity of the studied group of patients.

1. Kutlyeva L.R., Gilyazova I.R., Khusai-nova R.I., Zagidullin A.A., Khaliullin A.A., Klimentova E.A., Shafi-gina A.M., Pavlov V.N., Khusnutdinova E.K. Genetic screening for von Hippel-Lindau (VHL) gene mutations and analysis of allelic deletions of tumor suppressor genes in renal cell carcinoma patients from Bashkortostan. Meditsinskaya Genetika = Medical Genetics. 2012;12:27-35. (in Russian)

2. Audenet F., Yates D.R., Cancel-Tassin G., Cussenot O., Roupret M. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine. BJU Int. 2011; 109:1864-1870. DOI 10.1111/j.1464-410X.2011.10661.x.

3. Espana-Agusti J., Warren A., Chew S.K., Adams D.J., Matakidou A. Loss of PBRM1 rescues VHL dependent replication stress to promote renal carcinogenesis. Nat. Commun. 2017;8:2026. DOI 10.1038/s41467-017-02245-1.

4. Gao W., Li W., Xiao T., Liu X.S., Kaelin W.G. Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL-/- clear cell renal carcinoma. Proc. Natl. Acad. Sci. USA. 2017;114(5):1027-1032. DOI 10.1073/pnas.1619726114.

5. He N., Zheng H., Li P., Zhao Y., Zhang W., Song F., Chen K. miR-485-5p binding site SNP rs8752 in HPGD gene is associated with breast cancer risk. PLoS One. 2014;9(7):e102093. DOI 10.1371/joumal.pone.0102093.

6. Hogner A., Krause H., Jandrig B., Kasim M., Fuller F.T., Schostak M., Erbersdobler A., Patzak A., Kilic E. PBRM1 and VHL expression correlate in human clear cell renal cell carcinoma with differential association with patient’s overall survival. Urol. Oncol. 2018; 36(3):94.e1-94.e14. DOI 10.mi6/j.urolonc.2017.m.027.

7. Huang L., Peng Y., Zhong G., Xie W., Dong W., Wang B., Chen X., Gu P., He W., Wu S., Lin T., Huang J. PBRM1 suppresses bladder cancer by cyclin B1 induced cell cycle arrest. Oncotarget. 2015; 6(18):16366-16378. DOI 10.18632/oncotarget.3879.

8. Kapur P., Pena-Llopis S., Christie A., Zhrebker L., Pavia-Jimenez A., Rathmell W.K., Xie X.J., Brugarolas J. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol. 2013;14(2):159-167. DOI 10.1016/S1470-2045(12)70584-3.

9. Kluzek K., Srebniak M.I., Majer W., Ida A., Milecki T., Huminska K., van der Helm R.M., Silesian A., Wrzesinski T.M., Wojciechowicz J., Beverloo B.H., Kwias Z., Bluyssen H.A.R., Wesoly J. Genetic characterization of Polish ccRCC patients: somatic mutation analysis of PBRM1, BAP1 and KDMC5, genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNA. Oncotarget. 2017;8(17):28558-28574. DOI 10.18632/oncotarget.15331.

10. Lloyd J.T., Glass K.C. Biological function and histone recognition of family IV bromodomain-containing proteins. J. Cell Physiol. 2017; 233(3):1877-1886. DOI 10.1002/jcp.26010.

11. Macher-Goeppinger S., Keith M., Tagscherer K.E., Singer S., Winkler J., Hofmann T.G., Pahernik S., Duensing S., Hohenfellner M., Kopitz J., Schirmacher P., Roth W. PBRM1 (BAF180) protein is functionally regulated by p53-induced protein degradation in renal cell carcinomas. J. Pathol. 2015;237(4):460-471. DOI 10.1002/path.4592.

12. Niimi A., Hopkins S.R., Downs J.A., Masutani C. The BAH domain of BAF180 is required for PCNA ubiquitination. Mutat. Res. 2015; 779:16-23. DOI 10.1016/j.mrfmmm.2015.06.006.

13. Ricketts C.J., Linehan W.M. Intratumoral heterogeneity in kidney cancer. Nat. Genet. 2014;46:214-215. DOI 10.1038/ng.2904.

14. Sato Y., Yoshizato T., Shiraishi Y., Maekawa S., Okuno Y., Kamura T., Shimamura T., Sato-Otsubo A., Nagae G., Suzuki H., Nagata Y., Yoshida K., Kon A., Suzuki Y., Chiba K., Tanaka H., Niida A., Fuji-moto A., Tsunoda T., Morikawa T., Maeda D., Kume H., Sugano S., Fukayama M., Aburatani H., Sanada M., Miyano S., Homma Y., Ogawa S. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat. Genet. 2013;45(8):860-867. DOI 10.1038/ng.2699.

15. Shain A.H., Pollack J.R. The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PLoS One. 2013;8(1):e55119. DOI 10.1371/journal.pone.0055119.

16. Varela I., Tarpey P., Raine K., Huang D., Ong C.K., Stephens P., Davies H., Jones D., Lin M.L., Teague J., Bignell G., Butler A., Cho J., Dalgliesh G.L., Galappaththige D., Greenman C., Hardy C., Jia M., Latimer C., Lau K.W., Marshall J., McLaren S., Menzies A., Mudie L., Stebbings L., Largaespada D.A., Wessels L.F., Richard S., Kahnoski R.J., Anema J., Tuveson D.A., Perez-Mancera P.A., Mus-tonen V., Fischer A., Adams D.J., Rust A., Chan-on W., Subimerb C., Dykema K., Furge K., Campbell P.J., Teh B.T., Stratton M.R., Fut-real P.A. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature. 2011; 469(7331):539-542. DOI 10.1038/nature09639.

17. Wang Z., Kim T.B., Peng B., Karam J., Creighton C., Joon A., Kawaka-mi F., Trevisan P., Jonasch E., Chow C.W., Canales J.R., Tamboli P., Tannir N., Wood C., Monzon F., Baggerly K., Varella-Garcia M., Czerniak B., Wistuba I., Mills G., Shaw K., Chen K., Sircar K. Sarcomatoid renal cell carcinoma has a distinct molecular pathogenesis, driver mutation profile, and transcriptional landscape. Clin. Cancer Res. 2017;23(21):6686-6696. DOI 10.1158/1078-0432.CCR-17-1057.

18. Xia W., Nagase S., Montia A.G., Kalachikov S.M., Keniry M., Su T., Memeo L., Hibshoosh H., Parsons R. BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer. Cancer Res. 2008;68(6):1667-1674. DOI 10.1158/0008-5472.CAN-07-5276.